Company Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jerome Jabbour |
Contact Details
Address: 1545 Route 206 South, Suite 302 Bedminster, New Jersey 07921 United States | |
| Phone | 908 484 8805 |
| Website | matinasbiopharma.com |
Stock Details
| Ticker Symbol | MTNB |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001582554 |
| CUSIP Number | 576810303 |
| ISIN Number | US5768103039 |
| Employer ID | 46-3011414 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jerome D. Jabbour J.D. | Co-Founder, Chairman, Chief Executive Officer, President and Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2026 | 425 | Filing |
| Jul 14, 2026 | SCHEDULE 13G | Filing |
| Jul 13, 2026 | 425 | Filing |
| Jul 13, 2026 | 8-K | Current Report |
| Jun 26, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 424B7 | Filing |
| Jun 16, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2026 | 10-Q | Quarterly Report |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 10-K | Annual Report |